Jul 14, 2026 – 5.55pmASX-listed pharmaceutical micro-cap IDT Australia was the first to stalk Mayne Pharma’s South Australian manufacturing facility, but it wasn’t the last.Street Talk understands healthcare-focused private equity firm Genesis Capital weighed up a potential bid for the Salisbury plant, which was at the centre of Cosette’s abandoned $672 million bid for the company, earlier this year.Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Angira Bharadwaj is a co-editor of Street Talk. She covers IPOs, capital raises, mergers and acquisitions and other breaking news in Australia’s capital markets. Previously, she covered financial services, state, and federal politics. Send tips to @angirab.60 on encrypted messaging platform Signal.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?